CME Topic

Clinical Definition of COPD Exacerbations and Classification of Their Severity

Authors: Gaetano Caramori MD, PhD, Ian M. Adcock PhD, Alberto Papi MD

Abstract

Abstract:A standardized definition of chronic obstructive pulmonary disease (COPD) exacerbation still represents an unmet need in respiratory medicine; definitions currently rely on clinical empiricism with little evidence-based scientific support. Exacerbations of COPD are certainly clear events in the mind of practicing physicians. However, when one tries to provide simple concepts such as their definition and classification of severity, one realizes how little we know. Current symptom- and event-based definitions of a COPD exacerbation, as well as the classifications of the severity of COPD exacerbations, all have their own limitations. Efforts to assess the efficacy of new therapies in the treatment and prevention of COPD exacerbations have been hampered by the lack of a widely agreed upon and consistently used definition. There is a need for greater investment in research on COPD exacerbations in order to promote a better understanding of COPD exacerbations.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

References1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Bethesda, National Heart, Lung and Blood Institute, April 2001; NIH Publication No. 2701:1-100. Last update 2008. Available at: http://www.goldcopd.com. Accessed December 29, 2008.2. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease—2007 update. Can Respir J 2007;14(suppl B):5B–32B.O'DonnellDE]]AaronS]]BourbeauJ&etal;Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease—2007 update.Can Respir J2007145B-32B3. O'Donnell DE, Hernandez P, Kaplan A, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease—2008 update-highlights for primary care. Can Respir J 2008;15(suppl A):1A–8A.O'DonnellDE]]HernandezP]]KaplanA&etal;Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease—2008 update-highlights for primary care.Can Respir J2008151A-8A4. O'Brien C, Guest PJ, Hill SL, et al. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000;55:635–642.O'BrienC]]GuestPJ]]HillSL&etal;Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care.Thorax200055635-6425. Scarduelli C, Ambrosino N, Confalonieri M, et al. Prevalence and prognostic role of cardiovascular complications in patients with exacerbation of chronic obstructive pulmonary disease admitted to Italian respiratory intensive care units. Ital Heart J 2004;5:932–938.ScarduelliC]]AmbrosinoN]]ConfalonieriM&etal;Prevalence and prognostic role of cardiovascular complications in patients with exacerbation of chronic obstructive pulmonary disease admitted to Italian respiratory intensive care units.Ital Heart J20045932-9386. Lieberman D, Lieberman D, Gelfer Y, et al. Pneumonic vs nonpneumonic acute exacerbations of COPD. Chest 2002;122:1264–1270.LiebermanD]]LiebermanD]]GelferY&etal;Pneumonic vs nonpneumonic acute exacerbations of COPD.Chest20021221264-12707. Ambrosetti M, Ageno W, Spanevello A, et al. Prevalence and prevention of venous thromboembolism in patients with acute exacerbations of COPD. Thromb Res 2003;112:203–207.AmbrosettiM]]AgenoW]]SpanevelloA&etal;Prevalence and prevention of venous thromboembolism in patients with acute exacerbations of COPD.Thromb Res2003112203-2078. Erelel M, Cuhadaroglu C, Ece T, et al. The frequency of deep venous thrombosis and pulmonary embolus in acute exacerbation of chronic obstructive pulmonary disease. Respir Med 2002;96:515–518.ErelelM]]CuhadarogluC]]EceT&etal;The frequency of deep venous thrombosis and pulmonary embolus in acute exacerbation of chronic obstructive pulmonary disease.Respir Med200296515-5189. Rutschmann OT, Cornuz J, Poletti PA, et al. Should pulmonary embolism be suspected in exacerbation of chronic obstructive pulmonary disease? Thorax 2007;62:121–125.RutschmannOT]]CornuzJ]]PolettiPA&etal;Should pulmonary embolism be suspected in exacerbation of chronic obstructive pulmonary disease?Thorax200762121-12510. Tillie-Leblond I, Marquette CH, Perez T, et al. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med 2006;144:390–396.Tillie-LeblondI]]MarquetteCH]]PerezT&etal;Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors.Ann Intern Med2006144390-39611. Ramanuja S, Mastronarde J, Dowdeswell I, et al. A 44-year-old man with suspected exacerbation of COPD and atrial fibrillation. Chest 2004;125:2340–2344.RamanujaS]]MastronardeJ]]DowdeswellI&etal;A 44-year-old man with suspected exacerbation of COPD and atrial fibrillation.Chest20041252340-234412. Emerman CL, Cydulka RK. Evaluation of high-yield criteria for chest radiography in acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med 1993;22:680–684.EmermanCL]]CydulkaRKEvaluation of high-yield criteria for chest radiography in acute exacerbation of chronic obstructive pulmonary disease.Ann Emerg Med199322680-68413. Sherman S, Skoney JA, Ravikrishnan KP. Routine chest radiographs in exacerbations of chronic obstructive pulmonary disease. Diagnostic value. Arch Intern Med 1989;149:2493–2496.ShermanS]]SkoneyJA]]RavikrishnanKPRoutine chest radiographs in exacerbations of chronic obstructive pulmonary disease.Diagnostic value. Arch Intern Med19891492493-249614. Caramori G, Papi A. Pathogenic link between chronic obstructive pulmonary disease and squamous cell lung cancer. Expert Rev Respir Med 2007;1:171–175.CaramoriG]]PapiAPathogenic link between chronic obstructive pulmonary disease and squamous cell lung cancer.Expert Rev Respir Med20071171-17515. Anthonisen NR, Manfreda J, Warren CPW, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196–204.AnthonisenNR]]ManfredaJ]]WarrenCPW&etal;Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.Ann Intern Med1987106196-20416. Thompson AB, Daughton D, Robbins RA, et al. Intraluminal airway inflammation in chronic bronchitis. Characterization and correlation with clinical parameters. Am Rev Respir Dis 1989;140:1527–1537.ThompsonAB]]DaughtonD]]RobbinsRA&etal;Intraluminal airway inflammation in chronic bronchitis. Characterization and correlation with clinical parameters.Am Rev Respir Dis19891401527-153717. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006;173:1114–1121.PapiA]]BellettatoCM]]BraccioniF&etal;Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations.Am J Respir Crit Care Med20061731114-112118. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000;117(5 suppl 2):398S–401S.Rodriguez-RoisinRToward a consensus definition for COPD exacerbations.Chest2000117398S-401S19. Pauwels R, Calverley P, Buist AS, et al. COPD exacerbations: the importance of a standard definition. Respir Med 2004;98:99–107.PauwelsR]]CalverleyP]]BuistAS&etal;COPD exacerbations: the importance of a standard definition.Respir Med20049899-10720. Currie GP, Wedzicha JA. ABC of chronic obstructive pulmonary disease. Acute exacerbations. BMJ 2006;333:87–89.CurrieGP]]WedzichaJAABC of chronic obstructive pulmonary disease. Acute exacerbations.BMJ200633387-8921. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217–224.CasaburiR]]MahlerDA]]JonesPW&etal;A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease.Eur Respir J200219217-22422. Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial [Erratum in Lancet 2005;366:984]. Lancet 2005;365:1552–1560.23. Fabbri LM, Beghè B, Caramori G, et al. Similarities and discrepancies between exacerbations of asthma and chronic obstructive pulmonary disease. Thorax 1998;53:803–808.FabbriLM]]BeghèB]]CaramoriG&etal;Similarities and discrepancies between exacerbations of asthma and chronic obstructive pulmonary disease.Thorax199853803-80824. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297–1303.BurgePS]]CalverleyPM]]JonesPW&etal;Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.BMJ20003201297-130325. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449–456.CalverleyP]]PauwelsR]]VestboJ&etal;Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.Lancet2003361449-45626. Calverley P, Pauwels Dagger R, Lofdhal CG, et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD [Erratum in Eur Respir J 2006;27:440]. Eur Respir J 2005;26:406–413.27. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416–469.CazzolaM]]MacNeeW]]MartinezFJ&etal;Outcomes for COPD pharmacological trials: from lung function to biomarkers.Eur Respir J200831416-46928. Allegra L, Grassi C, Grossi E, et al. Ruolo degli antibiotici nel trattamento delle riacutizzazioni della bronchite cronica: risultati di uno studio italiano multicentrico. Ital J Chest Dis 1991;45:138–148.AllegraL]]GrassiC]]GrossiE&etal;Ruolo degli antibiotici nel trattamento delle riacutizzazioni della bronchite cronica: risultati di uno studio italiano multicentrico.Ital J Chest Dis199145138-14829. Donaldson GC, Seemungal TA, Patel IS, et al. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J 2003;22:931–936.DonaldsonGC]]SeemungalTA]]PatelIS&etal;Longitudinal changes in the nature, severity and frequency of COPD exacerbations.Eur Respir J200322931-93630. Seemungal TAR, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608–1613.SeemungalTAR]]DonaldsonGC]]BhowmikA&etal;Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease.Am J Respir Crit Care Med20001611608-161331. Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbations of severe chronic obstructive lung disease [Erratum in Am J Respir Crit Care Med 1997;155:386]. Am J Respir Crit Care Med 1996;154(4 pt 1):959–967.32. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl 2003;41:46s–53s.BurgeS]]WedzichaJACOPD exacerbations: definitions and classifications.Eur Respir J Suppl20034146s-53s33. Celli BR, Mac Nee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper [Erratum in Eur Respir J 2006;27:242]. Eur Respir J 2004;23:932–946.CelliBR]]Mac NeeWATS/ERS Task ForceStandards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper [Erratum in Eur Respir J 2006;27:242].Eur Respir J200423932-94634. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775–789.CalverleyPM]]AndersonJA]]CelliB&etal;Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.N Engl J Med2007356775-78935. Niewoehner DE. The role of systemic corticosteroids in acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Med 2002;1:243–248.NiewoehnerDEThe role of systemic corticosteroids in acute exacerbation of chronic obstructive pulmonary disease.Am J Respir Med20021243-24836. Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;2:CD004403.RamFS]]Rodriguez-RoisinR]]Granados-NavarreteA&etal;Antibiotics for exacerbations of chronic obstructive pulmonary disease.Cochrane Database Syst Rev20062CD00440337. Cao Z, Ong KC, Eng P, et al. Frequent hospital readmissions for acute exacerbation of COPD and their associated factors. Respirology 2006;11:188–195.CaoZ]]OngKC]]EngP&etal;Frequent hospital readmissions for acute exacerbation of COPD and their associated factors.Respirology200611188-19538. Tsoumakidou M, Tzanakis N, Voulgaraki O, et al. Is there any correlation between the ATS, BTS, ERS and GOLD COPD's severity scales and the frequency of hospital admissions? Respir Med 2004;98:178–183.TsoumakidouM]]TzanakisN]]VoulgarakiO&etal;Is there any correlation between the ATS, BTS, ERS and GOLD COPD's severity scales and the frequency of hospital admissions?Respir Med200498178-18339. Franciosi LG, Page CP, Celli BR, et al. Markers of exacerbation severity in chronic obstructive pulmonary disease. Respir Res 2006;7:74.FranciosiLG]]PageCP]]CelliBR&etal;Markers of exacerbation severity in chronic obstructive pulmonary disease.Respir Res200677440. Muller B, Tamm M. Biomarkers in acute exacerbation of chronic obstructive pulmonary disease: among the blind, the one-eyed is king. Am J Respir Crit Care Med 2006;174:848–849.MullerB]]TammMBiomarkers in acute exacerbation of chronic obstructive pulmonary disease: among the blind, the one-eyed is king.Am J Respir Crit Care Med2006174848-84941. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1618–1623.SeemungalT]]Harper-OwenR]]BhowmikA&etal;Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease.Am J Respir Crit Care Med20011641618-162342. Caramori G, Ito K, Contoli M, et al. Molecular mechanisms of respiratory virus-induced asthma and COPD exacerbations and pneumonia. Curr Med Chem 2006;13:2267–2290.CaramoriG]]ItoK]]ContoliM&etal;Molecular mechanisms of respiratory virus-induced asthma and COPD exacerbations and pneumonia.Curr Med Chem2006132267-229043. Stockley RA, O'Brien C, Pye A, et al. Relationship to sputum colour to nature and out-patient management of acute exacerbations of COPD. Chest 2000;117:1638–1645.StockleyRA]]O'BrienC]]PyeA&etal;Relationship to sputum colour to nature and out-patient management of acute exacerbations of COPD.Chest20001171638-164544. Stockley RA. Chronic obstructive pulmonary disease, neutrophils and bacteria: from science to integrated care pathways. Clin Med 2004;4:567–572.StockleyRAChronic obstructive pulmonary disease, neutrophils and bacteria: from science to integrated care pathways.Clin Med20044567-57245. Sapley E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax 2006;61:250–258.SapleyE]]StockleyRACOPD exacerbations. 2: aetiology.Thorax200661250-25846. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005;143:317–326.NiewoehnerDE]]RiceK]]CoteC&etal;Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial.Ann Intern Med2005143317-32647. Barnes PJ, Chowdhury B, Kharitonov SA, et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:6–14.BarnesPJ]]ChowdhuryB]]KharitonovSA&etal;Pulmonary biomarkers in chronic obstructive pulmonary disease.Am J Respir Crit Care Med20061746-1448. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomized, single-blinded intervention trial. Lancet 2004;363:600–607.Christ-CrainM]]Jaccard-StolzD]]BingisserR&etal;Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomized, single-blinded intervention trial.Lancet2004363600-60749. Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007;131:9–19.StolzD]]Christ-CrainM]]BingisserR&etal;Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy.Chest20071319-1950. Decramer M, Celli B, Tashkin DP, et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the uplift trial. COPD 2004;1:303–312.DecramerM]]CelliB]]TashkinDP&etal;Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the uplift trial.COPD20041303-31251. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of COPD exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19–26.WedzichaJA]]CalverleyPM]]SeemungalTA&etal;The prevention of COPD exacerbations by salmeterol/fluticasone propionate or tiotropium bromide.Am J Respir Crit Care Med200817719-2652. Miravitlles M, Ferrer M, Pont A, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2-year follow up study. Thorax 2004;59:387–395.MiravitllesM]]FerrerM]]PontA&etal;Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2-year follow up study.Thorax200459387-39553. Jones PW, Willits LR, Burge PS, et al. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003;21:68–73.JonesPW]]WillitsLR]]BurgePS&etal;Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations.Eur Respir J20032168-7354. Gompertz S, Bayley DL, Hill SL, et al. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax 2001;56:36–41.GompertzS]]BayleyDL]]HillSL&etal;Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD.Thorax20015636-4155. Contoli M, Caramori G, Mallia P, et al. A human rhinovirus model of chronic obstructive pulmonary disease exacerbations. Contrib Microbiol 2007;14:101–112.ContoliM]]CaramoriG]]MalliaP&etal;A human rhinovirus model of chronic obstructive pulmonary disease exacerbations.Contrib Microbiol200714101-11256. Kharitonov SA, Barnes PJ. Lipopolysaccharide challenge of humans as a model for chronic obstructive lung disease exacerbations. Contrib Microbiol 2007;14:83–100.KharitonovSA]]BarnesPJLipopolysaccharide challenge of humans as a model for chronic obstructive lung disease exacerbations.Contrib Microbiol20071483-10057. Hoogerwerf JJ, de Vos AF, Bresser P, et al. Lung inflammation induced by lipoteichoic acid or lipopolysaccharide in humans. Am J Respir Crit Care Med 2008;178:34–41.HoogerwerfJJ]]de VosAF]]BresserP&etal;Lung inflammation induced by lipoteichoic acid or lipopolysaccharide in humans.Am J Respir Crit Care Med200817834-41